Min H Kang

Summary

Affiliation: Texas Tech University Health Sciences Center
Country: USA

Publications

  1. doi request reprint Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma
    Min H Kang
    Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
    Br J Haematol 145:389-93. 2009
  2. ncbi request reprint Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study
    Min H Kang
    Cancer Center and Departments of Cell Biology and Biochemistry, Pharmacology and Neuroscience, Pediatrics, and Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, STOP 9445 79430 Lubbock, TX, USA
    BMC Res Notes 7:256. 2014
  3. pmc Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure
    Jason P Cooper
    Cancer Center and Departments of Cell Biology and Biochemistry Pharmacology and Neuroscience Internal Medicine Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
    Br J Pharmacol 163:1263-75. 2011
  4. pmc Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program
    Min H Kang
    Texas Tech University Health Sciences Center, Lubbock, Texas 79430 6450, USA
    Pediatr Blood Cancer 59:185-8. 2012
  5. doi request reprint Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program
    C Patrick Reynolds
    Cancer Center, Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas 79430 6450, USA
    Pediatr Blood Cancer 60:791-8. 2013
  6. ncbi request reprint Initial testing of lenalidomide by the pediatric preclinical testing program
    C Patrick Reynolds
    Texas Tech University Health Sciences Center, Lubbock, Texas, USA
    Pediatr Blood Cancer 57:606-11. 2011
  7. ncbi request reprint Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
    Min H Kang
    Texas Tech University Health Sciences Center, Lubbock, Texas
    Pediatr Blood Cancer 61:1486-9. 2014
  8. ncbi request reprint Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium
    Barry J Maurer
    Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, Texas Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
    Pediatr Blood Cancer 60:1801-8. 2013
  9. ncbi request reprint Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms
    Connor Hall
    Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79416, USA
    Clin Genitourin Cancer 11:10-9. 2013
  10. ncbi request reprint Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia
    Jason P Cooper
    School of Medicine, Texas Tech University HealthSciences Center, Lubbock, TX, USA
    Pediatr Blood Cancer 58:994-7. 2012

Collaborators

Detail Information

Publications14

  1. doi request reprint Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma
    Min H Kang
    Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
    Br J Haematol 145:389-93. 2009
    ..Both AMT and MTX significantly extended the event-free survival of mice bearing 3 out of 4 xenografts with equivalent activity...
  2. ncbi request reprint Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study
    Min H Kang
    Cancer Center and Departments of Cell Biology and Biochemistry, Pharmacology and Neuroscience, Pediatrics, and Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, STOP 9445 79430 Lubbock, TX, USA
    BMC Res Notes 7:256. 2014
    ....
  3. pmc Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure
    Jason P Cooper
    Cancer Center and Departments of Cell Biology and Biochemistry Pharmacology and Neuroscience Internal Medicine Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
    Br J Pharmacol 163:1263-75. 2011
    ..This study characterized metabolism of 4-HPR in humans and mice, and to explore the effects of ketoconazole, an inhibitor of CYP3A4, as a modulator to increase 4-HPR plasma levels in mice and to increase the low bioavailability of 4-HPR...
  4. pmc Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program
    Min H Kang
    Texas Tech University Health Sciences Center, Lubbock, Texas 79430 6450, USA
    Pediatr Blood Cancer 59:185-8. 2012
    ..No objective tumor responses were observed. In vivo AT13387 demonstrated only modest single agent activity...
  5. doi request reprint Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program
    C Patrick Reynolds
    Cancer Center, Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas 79430 6450, USA
    Pediatr Blood Cancer 60:791-8. 2013
    ..However, less is known regarding the relevance of this pathway in pediatric cancers. Here we have evaluated SAR245408, a novel small molecule PI3K inhibitor, against childhood cancer cell lines and xenografts...
  6. ncbi request reprint Initial testing of lenalidomide by the pediatric preclinical testing program
    C Patrick Reynolds
    Texas Tech University Health Sciences Center, Lubbock, Texas, USA
    Pediatr Blood Cancer 57:606-11. 2011
    ..On the basis of this varied pharmacological profile, lenalidomide is under investigation as a treatment for a range of oncologic indications...
  7. ncbi request reprint Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
    Min H Kang
    Texas Tech University Health Sciences Center, Lubbock, Texas
    Pediatr Blood Cancer 61:1486-9. 2014
    ..The modest activity observed for MLN0128 against the PPTP preclinical models is similar to that previously reported for another TOR kinase inhibitor. Pediatr Blood Cancer 2014; 61:1486-1489. © 2014 Wiley Periodicals, Inc. ..
  8. ncbi request reprint Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium
    Barry J Maurer
    Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, Texas Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
    Pediatr Blood Cancer 60:1801-8. 2013
    ....
  9. ncbi request reprint Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms
    Connor Hall
    Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79416, USA
    Clin Genitourin Cancer 11:10-9. 2013
    ..The objective of this review is to assess the involvement of Bcl-2 proteins as well as the preclinical and clinical activity of Bcl-2 inhibitors under evaluation for genitourinary neoplasms...
  10. ncbi request reprint Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia
    Jason P Cooper
    School of Medicine, Texas Tech University HealthSciences Center, Lubbock, TX, USA
    Pediatr Blood Cancer 58:994-7. 2012
    ..Pretreatment with N-acetylcysteine increased glutathione (P < 0.02)but did not alter 4-HPR cytotoxicity. Our data suggest that 4-HPR cytotoxicity is independent of glutathione under physiologic oxygen tension...
  11. pmc C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines
    Michael W Holliday
    School of Medicine Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America
    PLoS ONE 8:e74768. 2013
    ..The targeted increase of specific acyl chain dihydroceramides may constitute a novel anticancer approach. ..
  12. pmc National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing
    Min H Kang
    Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA
    Pediatr Blood Cancer 56:239-49. 2011
    ....
  13. pmc Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
    Min H Kang
    Cancer Center and the Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA
    Clin Cancer Res 15:1126-32. 2009
    ..Here, we review the role of the Bcl-2 family in apoptotic pathways and those agents that are known and/or designed to inhibit the anti-apoptotic Bcl-2 family of proteins...
  14. pmc Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis
    Chong Zhang
    Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79416, USA
    Leuk Res 36:342-9. 2012
    ..The combination significantly extended the event-free survival of mice carrying PTEN mutated xenografts. Our data suggest that PI3K/mTOR pathway inhibitors could benefit patients with PTEN mutated T-ALL...